Neutropenia and febrile neutropenia (FN) are common complications of myelosuppressive
chemotherapy. This review provides an up-to-date assessment of the patient and cost …

Purpose: Although studies have evaluated the risk and consequences of febrile neutropenia
(FN) among patients receiving cancer chemotherapy in US clinical practice, none have …

Despite major advances in prevention and treatment, FN remains one of the most frequent
and serious complications of cancer chemotherapy (ChT). It is a major cause of morbidity …

Chemotherapy-induced neutropenia (CIN) is a potentially fatal and common complication in
myelosuppressive chemotherapy. The timing and grade of CIN may play prognostic and …

Neutropenia with fever (febrile neutropenia [FN]) is a serious consequence of
myelosuppressive chemotherapy that usually results in hospitalization and the need for …

Background Chemotherapy-induced febrile neutropenia (FN) is a clinically important
complication that affects patient outcome by delaying chemotherapy doses or reducing dose …

Objective To examine the incidence, treatment, and consequences of febrile neutropenia
across inpatient and outpatient care settings. Methods Data were obtained from Humedica's …

Despite the overwhelming evidence for the role of granulocyte colony stimulating factors (G-
CSF) in managing febrile neutropenia (FN) risk, chemotherapy-induced neutropenia (CIN) …

Introduction Febrile neutropenia (FN) is a serious side-effect of myelosuppressive
chemotherapy. Several clinical trials and observational studies have evaluated the effects of …

BACKGROUND: Febrile neutropenia (FN) is a serious and potentially life‐threatening
condition that may develop in patients with cancer who receive myelosuppressive …